# Vertero Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/vertero-therapeutics

- Industry: Pharmaceuticals
- Headquarters: Woburn, US
- Website: www.vertero.com/
- Total disclosed funding: $81M
- Latest round: Series D (Jan 28, 2025)
- Investors on record: 9

## About

Founded in 2016 and headquartered in Woburn, US, Vertero Therapeutics, Inc., formerly known as Axial Therapeutics, specializes in therapeutics that leverage the gut-brain axis. In October 2025, Vertero Therapeutics, Inc. raised USD 20 million in series D funding from returning investors OneVentures and Seventure, with participation from unspecified investors.
Vertero Therapeutics specializes in the development of innovative small molecule therapeutics targeting the gut microbiome to address diseases and disorders such as autism spectrum disorder (ASD), Parkinson’s disease, liver disease, and oncology. Their lead product candidate, AB-2004, is aimed at treating irritability associated with autism and is currently in a global, randomized, placebo-controlled Phase 2 clinical trial, with results expected in Q1 2024. The company is also advancing its Microbial-Inspired Therapeutics® Platform, which explores the relationship between the microbiome and the nervous system to create transformative therapeutics, primarily targeting healthcare providers in North America and Europe.
The company intends to use the January 2025 funding to advance its lead program VT-5006 through Phase 1b trials, prepare for Phase 2, and expand its pipeline focused on neurodegenerative diseases.

## Funding rounds

- Series D, Jan 28, 2025, $19M — Seventure Partners, OneVentures
- Series C, Oct 22, 2021, $27M — Domain Associates, Seventure Partners, OneVentures, Longwood Fund, Taiho Ventures, UTokyo Innovation Platform, Autism Impact Fund, Corundum Systems Biology
- Series B, Jun 18, 2019, $5M — Taiho Ventures
- Series B, Nov 9, 2018, $20M — Domain Associates, Seventure Partners, Longwood Fund
- Series A, Nov 22, 2016, $9.6M — Domain Associates, Longwood Fund, Kairos Ventures

## Investors

- Domain Associates (https://capitalatlas.ai/funds/domain-associates) — Series A, Series B, Series C
- Longwood Fund (https://capitalatlas.ai/funds/longwood-fund) — Series A, Series B, Series C
- Kairos Ventures (https://capitalatlas.ai/funds/kairos-ventures) — Series A
- Seventure Partners (https://capitalatlas.ai/funds/seventure-partners) — Series B, Series C, Series D
- Taiho Ventures (https://capitalatlas.ai/funds/taiho-ventures) — Series B, Series C
- OneVentures (https://capitalatlas.ai/funds/oneventures) — Series C, Series D
- UTokyo Innovation Platform (https://capitalatlas.ai/funds/utokyo-innovation-platform) — Series C
- Autism Impact Fund (https://capitalatlas.ai/funds/autism-impact-fund) — Series C
- Corundum Systems Biology (https://capitalatlas.ai/funds/corundum-systems-biology) — Series C